Company announces management changes and further organizational
Fred Colen to lead CRM group
Paul LaViolette to retire from Company
NATICK, Mass., June 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) announced today that President and Chief Executive Officer Jim Tobin will be extending his tenure at the Company. The Company said Tobin plans to remain in his role for the foreseeable future.
The Company also announced that Fred Colen will become the President of its Cardiac Rhythm Management (CRM) group, and that Paul LaViolette, Chief Operating Officer (COO), will be retiring from the Company.
Colen has been with the Company since 1999 in a number of leadership positions. Most recently, he has served as Executive Vice President, Operations and Technology, CRM. Prior to this role, he served as Executive Vice President and Chief Technology Officer for the Company.
LaViolette first joined the Company in 1994, and he has also served in a number of leadership positions. He has been COO since 2005.
"I am very pleased to announce that Jim Tobin will be extending his
tenure as President and Chief Executive Officer of Boston Scientific," said
Pete Nicholas, Co-founder and Chairman of the Board of Boston Scientific.
"Two years ago we announced a similar extension. During the intervening
time, Jim has devoted the majority of his attention to the integration of
Guidant, while Paul has managed much of the day-to-day operations of the
rest of the Company. After two years of Jim's intense focus and successful
leadership, our CRM business and its new management team are re-vitalized
and well positioned to
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved